Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Decibel Therapeutics Inc (NQ: DBTX )

4.200 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Decibel Therapeutics Inc

Decibel Therapeutics to Present DB-020 Phase 1b Clinical Trial Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Data from interim analysis support DB-020 as a potential therapy to protect patients against irreversible hearing loss associated with cisplatin chemotherapy 
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Decibel Therapeutics to Participate in the Upcoming Barclays 2023 Gene Editing and Gene Therapy Summit
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Decibel Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices (AEMPS) to Initiate Clinical Development of Lead Gene Therapy Candidate DB-OTO
CTA authorization provides approval for the Company to expand its planned CHORD™ Phase 1/2 clinical trial of DB-OTO to patients in Spain aged two years and younger 
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Decibel Therapeutics Receives European Orphan Drug Designation for Lead Gene Therapy Candidate DB-OTO
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Decibel Therapeutics to Participate in the Upcoming Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Decibel Therapeutics Appoints Matthew Kapusta to its Board of Directors
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Decibel Therapeutics to Present at the Upcoming SVB Securities Global Biopharma Conference
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Decibel Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Update
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Decibel Therapeutics Announces Submission of Clinical Trial Applications for Lead Gene Therapy Candidate DB-OTO
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.